Presentation of Clinical Study Data, Prestigious Accolades, and Acquisitions - Research Report on Celgene, UnitedHealth,

Presentation of Clinical Study Data, Prestigious Accolades, and Acquisitions -
  Research Report on Celgene, UnitedHealth, AstraZeneca, Mylan, and Valeant

Editor Note: For more information about this release, please scroll to bottom.

PR Newswire

NEW YORK, December 25, 2013

NEW YORK, December 25, 2013 /PRNewswire/ --

Today, Analysts' Corner announced new research reports highlighting Celgene
Corporation (NASDAQ: CELG), UnitedHealth Group, Inc. (NYSE: UNH), AstraZeneca
PLC (NYSE: AZN), Mylan, Inc. (NASDAQ: MYL) and Valeant Pharmaceuticals
International, Inc. (NYSE: VRX). Today's readers may access these reports free
of charge - including full price targets, industry analysis and analyst
ratings - via the links below.

Celgene Corporation Research Report 

On December 10, 2013, Celgene Corporation's wholly-owned subsidiary, Celgene
International Sàrl (CIS) announced that it presented at the American Society
of Hematology Annual Meeting in New Orleans, Louisiana, updated analyses from
MM-003. According to the CIS, the MM-003 is a phase III study of pomalidomide
plus low-dose dexamethasone compared with high-dose dexamethasone in patients
with refractory multiple myeloma who failed therapy with both bortezomib and
lenalidomide, administered either alone or combination. The Company reported
that in a retrospective analysis, the increases in overall response rate (ORR)
and progression-free survival (PFS) were maintained for pomalidomide plus
low-dose dexamethasone compared with high-dose dexamethasone regardless of
modified high-risk cytogenetics (del (17p) or t(4;14)) (ORR: 25% vs. 9%,
P=0.071; PFS: 3.8 vs. 1.1 months, HR=0.44, P<0.001) or standard-risk
cytogenetics (ORR: 35% vs. 10%, P<0.001; PFS: 4.2 vs. 2.3 months, HR=0.55,
P<0.001). The Full Research Report on Celgene Corporation - including full
detailed breakdown, analyst ratings and price targets - is available to
download free of charge at:

http://www.AnalystsCorner.com/r/full_research_report/7f47_CELG

--

UnitedHealth Group, Inc. Research Report

On December 19, 2013, UnitedHealth Group, Inc. (UnitedHealth) reported that it
was honored with multiple awards for its online and mobile programs and
services that engage consumers in their health and make it easier for them to
navigate the health care system. UnitedHealthcare stated that it received
three Best in Biz Awards: myClaims Manager earned Gold in the Consumer Service
of the Year category; Health4Me received Silver in the Consumer Product of the
Year category; and UHC.TV took Bronze in the Website of the Year category.
Jeff Alter, CEO, UnitedHealthcare Employer & Individual, said, "These
personalized resources from UnitedHealthcare make it easier to navigate and
better understand the health care system, enabling people to play a greater
role in their health and well-being. We are grateful to receive these awards -
it affirms the value and usefulness of these innovative health programs and
services that help people live healthier lives." The Full Research Report on
UnitedHealth Group, Inc. - including full detailed breakdown, analyst ratings
and price targets - is available to download free of charge at:

http://www.AnalystsCorner.com/r/full_research_report/73e5_UNH

--

AstraZeneca PLC Research Report

On December 19, 2013, AstraZeneca PLC (AstraZeneca) announced an agreement
under which it will acquire the entirety of Bristol-Myers Squibb's interests
in the companies' diabetes alliance for an initial consideration of $2.7
billion on completion and up to $1.4 billion in regulatory, launch and
sales-related payments. The Company stated that it will pay various
sales-related royalty payments up until 2025, and may also pay up to $225
million when certain assets are subsequently transferred. Pascal Soriot, CEO
of AstraZeneca said, "Today's announcement reinforces AstraZeneca's long-term
commitment to diabetes, a core strategic area for us and an important platform
for returning AstraZeneca to growth. I would like to extend a warm welcome to
the Bristol-Myers Squibb people who are due to join us. My colleagues and I
look forward to working with them." The Full Research Report on AstraZeneca
PLC - including full detailed breakdown, analyst ratings and price targets -
is available to download free of charge at:

http://www.AnalystsCorner.com/r/full_research_report/09cc_AZN

--

Mylan, Inc. Research Report

On December 18, 2013, Mylan, Inc. (Mylan) announced that it has received all
regulatory approvals and has completed an agreement with Pfizer for the
exclusive worldwide rights to develop, manufacture and commercialize a novel
long-acting muscarinic antagonist (LAMA) compound for various indications.
Mylan's CEO, Heather Bresch said, "This acquisition further expands Mylan's
growing respiratory franchise, building upon the products we already have in
development, such as our generic Advair® program and our combination product
for the treatment of chronic obstructive pulmonary disease (COPD). By adding a
novel LAMA compound to our capabilities, we will have the opportunity to bring
additional combination products to market, including triple-combination
therapies, and further differentiate Mylan as a leader in this important
therapeutic area." The Full Research Report on Mylan, Inc. - including full
detailed breakdown, analyst ratings and price targets - is available to
download free of charge at:

http://www.AnalystsCorner.com/r/full_research_report/5a20_MYL

--

Valeant Pharmaceuticals International, Inc. Research Report

On December 16, 2013, Valeant Pharmaceuticals International, Inc. (Valeant)
announced that it has entered into a definitive agreement, under which the
Company will acquire all of the outstanding common stock of Solta Medical,
Inc. (Solta) for $2.92 per share in cash, representing a 40% premium to
Solta's closing share price on December 13, 2013, or a transaction value of c.
$250 million. J. Michael Pearson, Chairman and CEO of Valeant, commented, "The
acquisition of Solta will bring tremendous value to Valeant's current
aesthetic portfolio and together with our previous acquisitions, will create
the broadest aesthetic portfolio in the industry. Solta's leading aesthetic
devices are a natural fit with Valeant's facial injectables, professional skin
care products and physician dispensed products and will establish Valeant in a
strong leadership position as we continue to build our presence in the
aesthetic market." The Full Research Report on Valeant Pharmaceuticals
International, Inc. - including full detailed breakdown, analyst ratings and
price targets - is available to download free of charge at:

http://www.AnalystsCorner.com/r/full_research_report/9fdd_VRX

----

EDITOR NOTES:

1.This is not company news. We are an independent source and our views do
    not reflect the companies mentioned.
2.Information in this release is fact checked and produced on a best efforts
    basis and reviewed by Nidhi Vatsal, a CFA charterholder. However, we are
    only human and are prone to make mistakes. If you notice any errors or
    omissions, please notify us below.
3.This information is submitted as a net-positive to companies mentioned, to
    increase awareness for mentioned companies to our subscriber base and the
    investing public.
4.If you wish to have your company covered in more detail by our team, or
    wish to learn more about our services, please contact us at
    pubco@EquityNewsNetwork.com.
5.For any urgent concerns or inquiries, please contact us at
    compliance@EquityNewsNetwork.com.
6.Are you a public company? Would you like to see similar coverage on your
    company? Send us a full investors' package to
    research@EquityNewsNetwork.com for consideration.

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This
document, article or report is prepared and authored by Equity News Network.
An outsourced research services provider represented by Nidhi Vatsal, CFA, has
only reviewed the information provided by Equity News Network in this article
or report according to the Procedures outlined by Equity News Network. Equity
News Network is not entitled to veto or interfere in the application of such
procedures by the outsourced provider to the articles, documents or reports,
as the case may be.

NOT FINANCIAL ADVICE

Equity News Network makes no warranty, expressed or implied, as to the
accuracy or completeness or fitness for a purpose (investment or otherwise),
of the information provided in this document. This information is not to be
construed as personal financial advice. Readers are encouraged to consult
their personal financial advisor before making any decisions to buy, sell or
hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Equity News Network is not responsible for any error which may be occasioned
at the time of printing of this document or any error, mistake or shortcoming.
No liability is accepted by Equity News Network whatsoever for any direct,
indirect or consequential loss arising from the use of this document. Equity
News Network expressly disclaims any fiduciary responsibility or liability for
any consequences, financial or otherwise arising from any reliance placed on
the information in this document. Equity News Network does not (1) guarantee
the accuracy, timeliness, completeness or correct sequencing of the
information, or (2) warrant any results from use of the information. The
included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA
Institute.

SOURCE Analysts' Corner

Contact: Joe Thomas CONTACT PHONE: +1-310-496-8071 (North America)